REG - GSK PLC - China Breakthrough Therapy Designation for Blenrep

GSKAnnouncement

13/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240913:nRSM0429Ea&default-theme=true

RNS Number : 0429E  GSK PLC  13 September 2024

Issued: 13 September 2024, London UK

 

Blenrep (belantamab mafodotin) in combination receives Breakthrough Therapy
Designation in China for treatment of relapsed/refractory multiple myeloma

 

 * Granted based on results from phase III head-to-head DREAMM-7 trial

 * Designation expedites development of investigational drugs with potential for
substantial improvement over available therapies

 * Novel therapies needed in multiple myeloma as patients typically relapse or
stop responding to initial treatments
 1  (#_edn1)

 

GSK plc (LSE/NYSE: GSK) today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China has granted Breakthrough Therapy Designation (BTD) for Blenrep (belantamab mafodotin) combined with bortezomib plus dexamethasone (BorDex) for the treatment of relapsed or refractory multiple myeloma. NMPA BTD is intended to expedite the development of therapies for serious and life-threatening diseases for which there are no existing treatments or where initial evidence has shown an improvement in patient outcomes over available treatment options.
 2  (#_edn2)

Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK,
said: “Breakthrough Therapy Designation in China underscores the potential
for Blenrep to redefine outcomes for patients with multiple myeloma at or
after their first relapse. We look forward to continuing to work with the
health authority in China and others worldwide to bring Blenrep-based
combinations to patients as expeditiously as possible.”

 

BTD was granted based on the interim results of the phase III head-to-head
DREAMM-7 trial, which met its primary endpoint, showing statistically
significant and clinically meaningful improvements in progression-free
survival (PFS) for belantamab mafodotin combined with BorDex compared to
daratumumab plus BorDex in relapsed or refractory multiple myeloma.

 

A positive overall survival (OS) trend was observed but was not statistically
significant at the time of interim analysis. Follow-up for OS continues.
Results also showed clinically meaningful improvements across all other
secondary efficacy endpoints, including deeper and more durable responses
compared to the standard of care combinations. The safety and tolerability
profile of the belantamab mafodotin combination in the DREAMM-7 trial was
broadly consistent with the known profiles of the individual agents.

 

Multiple myeloma is a growing health concern in China with approximately
30,000 new cases each year 3  (#_edn3) . The incidence in China has doubled
and mortality has increased 1.5-fold in the past three decades. 4  (#_edn4)
This underscores the need for novel, efficacious treatment options for
patients in China, particularly those with progressing disease that has become
resistant to the current standard of care.

 

About multiple myeloma

Multiple myeloma is the third most common blood cancer globally and is
generally considered treatable but not curable. 5  (#_edn5) (, 6  (#_edn6) )
There are approximately more than 180,000 new cases of multiple myeloma
diagnosed globally each year. 7  (#_edn7)  Research into new therapies is
needed as multiple myeloma commonly becomes refractory to available
treatments. 8  (#_edn8)

 

About DREAMM-7

The DREAMM-7 phase III clinical trial is a multicentre, open-label, randomised
trial evaluating the efficacy and safety of belantamab mafodotin in
combination with BorDex compared to a combination of daratumumab and BorDex in
patients with relapsed/refractory multiple myeloma who previously were treated
with at least one prior line of multiple myeloma therapy, with documented
disease progression during or after their most recent therapy.

 

A total of 494 participants were randomised at a 1:1 ratio to receive either
belantamab mafodotin in combination with BorDex or a combination of
daratumumab and BorDex. Belantamab mafodotin was scheduled to be dosed at
2.5mg/kg intravenously every three weeks.

 

The primary endpoint is PFS as per an independent review committee. The key
secondary endpoints include OS, duration of response (DOR), and minimal
residual disease (MRD) negativity rate as assessed by next-generation
sequencing. Other secondary endpoints include overall response rate (ORR),
safety, and patient reported and quality of life outcomes.

 

Results from DREAMM-7 were first presented
(https://www.gsk.com/en-gb/media/press-releases/dreamm-7-phase-iii-trial-shows-pfs-improvement-and-strong-os-trend-for-blenrep-combo-versus-soc-combo-in-multiple-myeloma/)
 9  (#_edn9) at the American Society of Clinical Oncology (ASCO) Plenary
Series in February 2024, shared in an encore presentation at the 2024 ASCO
Annual Meeting, and published in the New England Journal of Medicine.

 

About Blenrep

Blenrep is an antibody-drug conjugate comprising a humanised B-cell
maturation antigen monoclonal antibody conjugated to the cytotoxic agent
auristatin F via a non-cleavable linker. The drug linker technology is
licensed from Seagen Inc.; the monoclonal antibody is produced using
POTELLIGENT Technology licensed from BioWa Inc., a member of the Kyowa Kirin
Group.

 

Blenrep is approved as monotherapy in Hong Kong, Israel and Singapore. Refer
to the local Summary of Product Characteristics for a full list of adverse
events and complete important safety information.

 

GSK in oncology

Oncology is an emerging therapeutic area for GSK where we are committed to
maximising patient survival with a current focus on haematologic malignancies,
gynaecologic cancers, and other solid tumours through breakthroughs in
immuno-oncology and tumour-cell targeting therapies.

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com.

 

 GSK enquiries
 Media:               Tim Foley          +44 (0) 20 8047 5502  (London)
                      Dan Smith          +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn     +1 202 603 5003       (Washington DC)
                      Lyndsay Meyer      +1 202 302 4595       (Washington DC)

 Investor Relations:  Nick Stone         +44 (0) 7717 618834   (London)
                      James Dodwell      +44 (0) 20 8047 2406  (London)
                      Mick Readey        +44 (0) 7990 339653   (London)
                      Josh Williams      +44 (0) 7385 415719   (London)
                      Camilla Campbell   +44 (0) 7803 050238   (London)
                      Steph Mountifield  +44 (0) 7796 707505   (London)
                      Jeff McLaughlin    +1 215 751 7002       (Philadelphia)
                      Frannie DeFranco   +1 215 751 4855       (Philadelphia)

 

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described under
Item 3.D ''Risk factors'' in GSK's Annual Report on Form 20-F for 2023, and
GSK's Q2 Results for 2024.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

 1  (#_ednref1) Moreau P., Kumar S, San Miguel J, et al. Treatment of relapsed
and refractory multiple myeloma: recommendations from the International
Myeloma Working Group. The Lancet Oncology, Volume 22, Issue 3,
e105-e118.doi:10.1016/S1470-2045(20)30756-7.

 2  (#_ednref2) China Drug Registration Regulation. Available at:
http://www.gov.cn/gongbao/content/2020/content_5512563.htm. Accessed 12
September 2024.

 3  (#_ednref3) Global Cancer Observatory. International Agency for Research
on Cancer. World Health Organization. China fact sheet. Available at:
https://gco.iarc.who.int/media/globocan/factsheets/populations/160-china-fact-sheet.pdf.
Accessed 12 September 2024.

 4  (#_ednref4) Liu J, Liu W, Mi L, et al. Burden of multiple myeloma in
China: an analysis of the Global Burden of Disease, Injuries, and Risk Factors
Study 2019. Chin Med J (Engl). 2023;136(23):2834-2838. Published 2023 Dec 5.
doi:10.1097/CM9.0000000000002600.

 5  (#_ednref5) Sung H, Ferlay J, Siegel R, et al. Global Cancer Statistics
2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers
in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.
doi:10.3322/caac.21660.

 6  (#_ednref6) Kazandjian D. Multiple myeloma epidemiology and survival: A
unique malignancy. Semin Oncol.
2016;43(6):676Ð681.doi:10.1053/j.seminoncol.2016.11.004.

 7  (#_ednref7) Global Cancer Observatory. International Agency for Research
on Cancer. World Health Organization. Multiple Myeloma fact sheet. Available
at:
https://gco.iarc.who.int/media/globocan/factsheets/cancers/35-multiple-myeloma-fact-sheet.pdf.
Accessed 12 September 2024.

 8  (#_ednref8) Nooka AK, Kastritis E, Dimopoulos MA. Treatment options for
relapsed and refractory multiple myeloma. Blood. 2015;125(20).
doi:10.1182/blood-2014-11-568923.

 9  (#_ednref9) GSK press release issued 05 February 2024. DREAMM-7 phase III
trial shows Blenrep combination nearly tripled median progression-free
survival versus standard of care combination in patients with
relapsed/refractory multiple myeloma. Available at:
https://www.gsk.com/en-gb/media/press-releases/dreamm-7-phase-iii-trial-shows-pfs-improvement-and-strong-os-trend-for-blenrep-combo-versus-soc-combo-in-multiple-myeloma/.
Accessed 12 September 2024.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCKZGMLLZNGDZM